1. Opening Hook
Influx just wrapped up its maiden earnings call, and instead of nervous first-date energy, management showed up like a veteran who already knows the menu. While most SMEs blame rains, macros, or Mercury retrograde, Influx blamed… rains only once—and still promised to double the business. Classic.
In a market where “capacity expansion” usually means one PowerPoint slide and zero execution, Influx quietly installed machines, ramped output, and expanded margins—using internal cash. IPO money is still chilling in the bank, probably earning more interest than some listed peers’ ROCE.
Margins expanded, cash piled up, and management spoke confidently about ₹450–500 Cr revenue by FY29, without voice cracks. The call felt less like guidance and more like a flex.
Read on. The interesting stuff comes after the big numbers.
2. At a Glance
- Revenue ₹66.8 Cr (+39% YoY) – Apparently, nutraceutical demand didn’t get the recession memo.
- EBITDA ₹14.7 Cr (+61% YoY) – Operating leverage finally decided to show up for work.
- EBITDA Margin 22% (+302 bps) – Turns out scale can be profitable. Shocking.
- PAT ₹10 Cr (+78% YoY) – Profits sprinted faster than topline. CFO smiled quietly.
- Cash ₹36.6 Cr – IPO funds parked safely, not YOLO-ed into vanity capex.
3. Management’s Key Commentary (Decoded)
“We launch approximately two new products every day.”
(Translation: Our R&D kitchen never sleeps, and clients keep ordering seconds 😏)
“All expansions were funded through internal accruals.”
(Translation: No debt, no drama, no banker uncle calling daily.)
“We are at ~65% capacity utilization in nutraceuticals currently.”
(Translation: Growth runway still long; machines haven’t even warmed up yet.)
“Cosmetics margins are better than nutraceuticals.”
(Translation: Beauty really does pay more than health.)
“Veterinary today is where nutraceuticals were in 2010.”
(Translation: Early-cycle opportunity, low competition, high excitement 🐶)
“We can reach ₹450–500 Cr revenue by FY29.”
(Translation: Capacity math checks out; execution is the only exam left.)
“We want to double the business by
